ECSIN LAB in vitro models for a nutraceutical approach to combating prostate inflammation
The Mérieux NutriSciences | ECSIN LAB is a cutting-edge research laboratory specializing in advanced in vitro models, offering a comprehensive and exclusive platform for preclinical testing of formulations, ingredients, and final products. This unique service allows for the precise simulation of biological barriers and target organs, essential for determining the absorption and efficacy of substances in a controlled, reproducible environment.
In vitro models, by replicating the structural and functional complexity of human tissues, provide an invaluable alternative to in vivo studies. They facilitate cost-effective, rapid, and highly controlled screening processes. Absorption studies conducted in these models are particularly crucial for the preliminary evaluation of formulations and ingredients, allowing for multiple screening assays before progressing to more complex stages of product development. Moreover, target-specific in vitro systems enable a detailed understanding of the mechanisms of action, critical for assessing product efficacy at the molecular and cellular levels.
The precision and versatility of ECSIN LAB’s in vitro platforms make it possible to perform high-throughput screenings and mechanistic studies, streamlining product development while minimizing the need for animal testing, in compliance with regulatory standards such as those outlined by the EMA and FDA.
Mérieux NutriSciences | ECSIN LAB continues its researches in this field to applying the versatility of in vitro models developed to different sectors. In the following article, the research team has applied the in vitro motels to study a nutraceutical approach to combating prostate inflammation “Evaluation of the immunomodulatory effects of a probiotics and natural extract-based formulation in bacterial-induced prostatitis”.
The in vitro models applied
In vitro epithelial models that replicate the digestive system are essential tools in modern research and product development. These models mimic the structure and function of the human gastrointestinal (GI) tract, allowing scientists to study complex processes like absorption, metabolism, and interactions between ingested substances and the digestive mucosa. By simulating the different layers of the GI epithelium, from the stomach to the intestines, these systems provide a highly controlled environment for evaluating the impact of food, drugs, and nutraceuticals on the digestive system. One of the key advantages of in vitro digestive models is their ability to offer insights into absorption and permeability mechanisms. These models can be tailored to represent specific regions of the GI tract, such as the stomach, small intestine, or colon, allowing researchers to focus on particular stages of digestion or drug absorption. Additionally, they provide a platform for investigating the bioavailability of active ingredients, the stability of compounds during digestion, and potential toxicity or irritation caused by various substances.
In Vitro Intestinal Epithelium Model. The intestinal in vitro model used is based on the human intestinal adenocarcinoma cells Caco-2, cultured as a functional monolayer. Upon long-term culture in confluent monolayers, Caco-2 cells differentiate into intestinal enterocyte-like cells with mature features, such as polarization, apical brush borders and formation of tight junctions.
In Vitro Model of Innate Immune System. Human THP-1 monocytes were maintained in THP-1 cell complete medium. Macrophage differentiation was induced by incubating THP-1 with phorbol myristate acetate (PMA) for 24 h. Culture medium was then replaced and cells left to rest for an additional 48 h before exposure to active principles, their mix and the inflammatory stimulus, E. coli.
The aim of the study
The primary aim of the study was to investigate the anti-inflammatory properties of this nutraceutical formulation in an in vitro model of bacterial-induced prostatitis. By focusing on the reduction of proinflammatory cytokines, the study sought to assess the formulation’s potential as a preventive and therapeutic option for managing bacterial prostatitis and mitigating its progression to more serious conditions.
The results
The results of the study were promising, demonstrating that:
- the nutraceutical formulation effectively reduced the release of key proinflammatory cytokines, such as IL-1β, MCP-1, MCP-2, and IL-8;
- the individual components of the formulation – pumpkin extract, bromelain, and Lactobacillus rhamnosus – each contributed to this effect, acting on different targets within the inflammatory pathway.
This multi-faceted approach shows potential for not only alleviating the symptoms of prostatitis but also for reducing the long-term risks associated with chronic prostate inflammation, such as prostate cancer.
Conclusion
The findings highlight the potential of this nutraceutical formulation as an effective tool in the prevention and treatment of bacterial prostatitis. By targeting the inflammatory responses at a molecular level, this approach offers a promising alternative to traditional treatments, with the added benefits of natural ingredients and probiotics. Further research and clinical trials will be essential to confirm these results and to explore the formulation’s full therapeutic potential.
To learn more about our revolutionary research on Evaluation of the Immunomodulatory Effects of a Probiotics and Natural Extract-Based Formulation in Bacterial-Induced Prostatitis and our commitment to advancing human health, read the complete article.
